Novel antigen modulation technology that controls T cells to guide the immune system
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognise or target cells correctly.
Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.
This approach marks a fundamental shift in how we treat people living with cancers, autoimmune disorders, and infectious diseases.
We seek to solve immune dysfunction.
Progressing through the clinic
We uncover novel biology to develop treatments for disease areas with significant unmet need.
Our lead antigen modulator (GWRD5769) delivered strong results during a phase 1/2 trial in oncology, demonstrating proof-of-mechanism and target engagement.
We have active discovery and development programs across oncology, autoimmunity and virology.
Our team and collaborators are experts in the field of antigen modulation.
A new therapeutic branch
We are the first to explore the untapped potential of changing the first step of the T cell signaling cascade - Signal 1 - despite its fundamental importance in T cell activation.
Changing the treatment paradigm
We're on a mission to deliver a new therapeutic class of treatments to help people living with cancers, autoimmune disorders, and infectious diseases.
We're looking for talented individuals to join our award-winning team. Do you have what it takes?
